News & Updates

In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

In solid organ transplant recipients with moderate symptoms of SARS-CoV-2 infection, early administration of a 3-day remdesivir course appears to effectively prevent COVID-19-related hospitalization as well as the clinical worsening of those who are hospitalized, according to a study.

Short-term concurrent androgen deprivation therapy (ADT) results in markedly worse overall survival (OS) among intermediate-risk (IR) prostate cancer patients on dose-escalated intensity modulated radiation therapy (IMRT) with daily image-guided RT, reveals a study.